
KOD
Healthcare · Biotechnology · $7.27B market cap
$111.19+2.94 (+2.7%)Nov 13, 4:15 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +1.2% over 90 days · 30-day revisions 2 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | After the close | -1.01 | -1.05 | -4.0% |
| Aug 13, 2026 | After the close | -0.97 | -1.05 | -8.2% |
| May 7, 2026 | After the close | -1.01 | -0.94 | +6.9% |
| Mar 26, 2026 | Time not confirmed | -1.01 | -1.04 | -3.0% |
| Nov 13, 2025 | After the close | -1.04 | -1.16 | -11.5% |
| Aug 13, 2025 | After the close | -1.05 | -1.03 | +1.9% |
| May 14, 2025 | After the close | -0.87 | -1.09 | -25.3% |
| Mar 26, 2025 | Before the open | -0.86 | -0.84 | +2.8% |
| Nov 14, 2024 | After the close | -0.90 | -0.84 | +6.7% |
| Aug 14, 2024 | After the close | -0.85 | -0.86 | -1.2% |
| May 15, 2024 | After the close | -1.06 | -0.82 | +22.6% |
| Mar 28, 2024 | Before the open | -0.77 | -1.13 | -46.8% |
| Nov 14, 2023 | After the close | -1.35 |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical…
| -0.95 |
| +29.6% |
| Aug 14, 2023 | After the close | -1.15 | -1.53 | -33.0% |
| May 15, 2023 | After the close | -1.37 | -1.35 | +1.5% |
| Mar 28, 2023 | After the close | -1.52 | -1.35 | +11.2% |
| Nov 9, 2022 | After the close | -1.71 | -1.47 | +14.0% |
| Aug 9, 2022 | After the close | -1.74 | -1.74 | 0.0% |
| May 10, 2022 | After the close | -1.56 | -1.83 | -17.3% |
| Mar 1, 2022 | After the close | -1.36 | -1.79 | -31.6% |
| Nov 9, 2021 | After the close | -1.18 | -1.30 | -10.2% |
| Aug 9, 2021 | After the close | -1.03 | -1.08 | -4.9% |
| May 10, 2021 | Before the open | -0.98 | -0.98 | 0.0% |
| Mar 1, 2021 | Before the open | -0.80 | -0.97 | -21.3% |
| Nov 9, 2020 | Before the open | -0.70 | -0.80 | -14.3% |
| Aug 10, 2020 | Before the open | -0.57 | -0.58 | -1.8% |
| May 11, 2020 | Before the open | -0.46 | -0.54 | -17.4% |
| Mar 16, 2020 | Before the open | -0.35 | -0.40 | -14.3% |
| Nov 12, 2019 | Before the open | -0.33 | -0.33 | 0.0% |
| Aug 14, 2019 | Before the open | -0.29 | -0.31 | -6.9% |
| May 15, 2019 | Before the open | -0.37 | -0.21 | +43.2% |
| Mar 27, 2019 | After the close | -0.30 | -0.25 | +16.7% |
| Nov 16, 2018 | After the close | -0.26 | -0.38 | -46.2% |
| Aug 29, 2018 | Time not confirmed | — | -1.01 | — |